Literature DB >> 20962032

Bis-halogen-anthraniloyl-substituted nucleoside 5'-triphosphates as potent and selective inhibitors of Bordetella pertussis adenylyl cyclase toxin.

Jens Geduhn1, Stefan Dove, Yuequan Shen, Wei-Jen Tang, Burkhard König, Roland Seifert.   

Abstract

Whooping cough is caused by Bordetella pertussis and still constitutes one of the top five causes of death in young children, particularly in developing countries. The calmodulin-activated adenylyl cyclase (AC) toxin CyaA substantially contributes to disease development. Thus, potent and selective CyaA inhibitors would be valuable drugs for the treatment of whooping cough. However, it has been difficult to obtain potent CyaA inhibitors with selectivity relative to mammalian ACs. Selectivity is important for reducing potential toxic effects. In a previous study we serendipitously found that bis-methylanthraniloyl (bis-MANT)-IMP is a more potent CyaA inhibitor than MANT-IMP (Mol Pharmacol 72:526-535, 2007). These data prompted us to study the effects of a series of 32 bulky mono- and bis-anthraniloyl (ANT)-substituted nucleotides on CyaA and mammalian ACs. The novel nucleotides differentially inhibited CyaA and ACs 1, 2, and 5. Bis-ANT nucleotides inhibited CyaA competitively. Most strikingly, bis-Cl-ANT-ATP inhibited CyaA with a potency ≥100-fold higher than ACs 1, 2, and 5. In contrast to MANT-ATP, bis-MANT-ATP exhibited low intrinsic fluorescence, thereby substantially enhancing the signal-to noise ratio for the analysis of nucleotide binding to CyaA. The high sensitivity of the fluorescence assay revealed that bis-MANT-ATP binds to CyaA already in the absence of calmodulin. Molecular modeling showed that the catalytic site of CyaA is sufficiently spacious to accommodate both MANT substituents. Collectively, we have identified the first potent CyaA inhibitor with high selectivity relative to mammalian ACs. The fluorescence properties of bis-ANT nucleotides facilitate development of a high-throughput screening assay.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962032      PMCID: PMC3014302          DOI: 10.1124/jpet.110.174219

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  28 in total

1.  Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough.

Authors:  Sandriyana Soelaiman; Binqing Q Wei; Pamela Bergson; Young-Sam Lee; Yuequan Shen; Milan Mrksich; Brian K Shoichet; Wei-Jen Tang
Journal:  J Biol Chem       Date:  2003-04-03       Impact factor: 5.157

2.  Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins.

Authors:  Yuequan Shen; Young-Sam Lee; Sandriyana Soelaiman; Pamela Bergson; Dan Lu; Alice Chen; Kathy Beckingham; Zenon Grabarek; Milan Mrksich; Wei-Jen Tang
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

3.  Insights into nucleotide binding in protein kinase A using fluorescent adenosine derivatives.

Authors:  Q Ni; J Shaffer; J A Adams
Journal:  Protein Sci       Date:  2000-09       Impact factor: 6.725

4.  Inhibition of Bordetella pertussis and Bacillus anthracis adenylyl cyclases by polyadenylate and "P"-site agonists.

Authors:  R A Johnson; I Shoshani
Journal:  J Biol Chem       Date:  1990-11-05       Impact factor: 5.157

5.  Molecular basis for P-site inhibition of adenylyl cyclase.

Authors:  J J Tesmer; C W Dessauer; R K Sunahara; L D Murray; R A Johnson; A G Gilman; S R Sprang
Journal:  Biochemistry       Date:  2000-11-28       Impact factor: 3.162

6.  Is there a rate-limiting step before GTP cleavage by H-ras p21?

Authors:  H Rensland; A Lautwein; A Wittinghofer; R S Goody
Journal:  Biochemistry       Date:  1991-11-19       Impact factor: 3.162

7.  New ribose-modified fluorescent analogs of adenine and guanine nucleotides available as substrates for various enzymes.

Authors:  T Hiratsuka
Journal:  Biochim Biophys Acta       Date:  1983-02-15

8.  2'(3')-O-(N-methylanthraniloyl)-substituted GTP analogs: a novel class of potent competitive adenylyl cyclase inhibitors.

Authors:  Andreas Gille; Roland Seifert
Journal:  J Biol Chem       Date:  2003-02-03       Impact factor: 5.157

9.  Pro-nucleotide inhibitors of adenylyl cyclases in intact cells.

Authors:  Wolfgang H G Laux; Praveen Pande; Ilana Shoshani; Junyuan Gao; Valérie Boudou-Vivet; Gilles Gosselin; Roger A Johnson
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

10.  Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides.

Authors:  Andreas Gille; Gerald H Lushington; Tung-Chung Mou; Michael B Doughty; Roger A Johnson; Roland Seifert
Journal:  J Biol Chem       Date:  2004-02-23       Impact factor: 5.157

View more
  13 in total

1.  Interactions of Bordetella pertussis adenylyl cyclase toxin CyaA with calmodulin mutants and calmodulin antagonists: comparison with membranous adenylyl cyclase I.

Authors:  Dominik Schuler; Carolin Lübker; Gerald H Lushington; Wei-Jen Tang; Yuequan Shen; Mark Richter; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2012-01-13       Impact factor: 5.858

2.  Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Authors:  Hesham Taha; Stefan Dove; Jens Geduhn; Burkhard König; Yuequan Shen; Wei-Jen Tang; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-09-24       Impact factor: 3.000

3.  Structural basis for the high-affinity inhibition of mammalian membranous adenylyl cyclase by 2',3'-o-(N-methylanthraniloyl)-inosine 5'-triphosphate.

Authors:  Melanie Hübner; Anshuman Dixit; Tung-Chung Mou; Gerald H Lushington; Cibele Pinto; Andreas Gille; Jens Geduhn; Burkhard König; Stephen R Sprang; Roland Seifert
Journal:  Mol Pharmacol       Date:  2011-04-15       Impact factor: 4.436

4.  Structure-activity relationships for the interactions of 2'- and 3'-(O)-(N-methyl)anthraniloyl-substituted purine and pyrimidine nucleotides with mammalian adenylyl cyclases.

Authors:  Cibele Pinto; Gerald H Lushington; Mark Richter; Andreas Gille; Jens Geduhn; Burkhard König; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2011-05-18       Impact factor: 5.858

Review 5.  An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis.

Authors:  Lernik Ohanjanian; Kenneth E Remy; Yan Li; Xizhong Cui; Peter Q Eichacker
Journal:  Expert Opin Investig Drugs       Date:  2015-04-28       Impact factor: 6.206

Review 6.  Inhibitors of membranous adenylyl cyclases.

Authors:  Roland Seifert; Gerald H Lushington; Tung-Chung Mou; Andreas Gille; Stephen R Sprang
Journal:  Trends Pharmacol Sci       Date:  2011-11-17       Impact factor: 14.819

Review 7.  International Union of Basic and Clinical Pharmacology. CI. Structures and Small Molecule Modulators of Mammalian Adenylyl Cyclases.

Authors:  Carmen W Dessauer; Val J Watts; Rennolds S Ostrom; Marco Conti; Stefan Dove; Roland Seifert
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

8.  Synthesis and evaluation of fluorescent cap analogues for mRNA labelling.

Authors:  Marcin Ziemniak; Mariusz Szabelski; Maciej Lukaszewicz; Anna Nowicka; Edward Darzynkiewicz; Robert E Rhoads; Zbigniew Wieczorek; Jacek Jemielity
Journal:  RSC Adv       Date:  2013       Impact factor: 3.361

Review 9.  Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Authors:  Martin Göttle; Stefan Dove; Roland Seifert
Journal:  Toxins (Basel)       Date:  2012-07-06       Impact factor: 4.546

10.  Analysis of substrate specificity and kinetics of cyclic nucleotide phosphodiesterases with N'-methylanthraniloyl-substituted purine and pyrimidine 3',5'-cyclic nucleotides by fluorescence spectrometry.

Authors:  Daniel Reinecke; Frank Schwede; Hans-Gottfried Genieser; Roland Seifert
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.